Printed From:

Proven for
prophylaxis of deep
vein thrombosis in
medically ill
patients

LOVENOX treatment lowered the risk of deep vein thrombosis (DVT) which may lead to pulmonary embolism (PE).1

Outcomes of medical patients with restricted mobility treated with 7 days (median duration) of 40 mg LOVENOX daily subcutaneously:

Relative risk reduction of
63%
and ARR=7.5% in DVT/PE events;
LOVENOX
vs placebo (4.4% vs 11.9%);
P=0.0003a;
N=722.

At approximately 3 months following enrollment, the incidence of venous thromboembolism remained lower in the LOVENOX 40 mg treatment group versus the placebo treatment group.

Safety endpoints (LOVENOX vs placebo)1
Major bleeding: 3(<1%) vs 2(<1%)

Bleeding complications were considered major: (1) if the hemorrhage caused a significant clinical event, (2) if the hemorrhage caused a decrease in hemoglobin of >= 2 g/dL or transfusion of 2 or more units of blood products. Retroperitoneal and intracranial hemorrhages were always considered major although none were reported during the trial. The rates represent major bleeding on study medication up to 24 hours after last dose.

Adverse reactions occurring at ≥2% incidence in LOVENOX-treated medically iII patients
LOVENOX
(%)
Placebo
(%)
Dyspnea
3.3
5.2
Thrombocytopenia
2.8
2.8
Confusion
2.2
1.1
Diarrhea
2.2
1.7
Nausea
2.5
1.7

In a study of medical patients with severely restricted mobility during acute illness, LOVENOX was dosed for no more than 14 days, and most patients were treated for 6 to 11 days in this study (median 7 days).

ARR=absolute risk reduction
aP value calculated based on chi-square test.1

Acutely ill medical
patient populations

In a double blind study, medical patients with severely restricted mobility during acute illness were treated with LOVENOX 20 mg or 40 mg once a day subcutaneously. The study included patients with heart failure (NYHA Class III or IV); acute respiratory failure or chronic respiratory insufficiency; acute infection; or acute rheumatic disorder. A total of 1,073 patients, ages ranging from 40 to 97 years, were treated.


DVT Prophylaxis

In Acutely Ill Medical Patients

LOVENOX has proven outcomes in once-daily dosing of medically ill patients, offering:

  • Fixed dosing of 40 mg for up to 14 days
  • No monitoring of aPTT
    • Periodic complete blood counts, including platelet count, and stool occult blood tests are recommended during the course of treatment with Lovenox
  • No dose adjustments for concomitant medication
    • If coadministration is essential, conduct close clinical and laboratory monitoring
Prophylaxis in medical patients
Medical patients during acute illness
Dosing40 mg subcutaneously once daily
Duration
of
therapy
  • Median: 7 days
  • Usual: 6 to 11 days
  • Maximum: 14 days

Many hospitalized, acutely ill medical patients and surgical patients may develop DVT/PE as outpatients.

Appropriate length of DVT prophylaxis begins in the hospital and may continue with outpatient therapy.

Average hospital length of stay (LOS) vs recommended duration of prophylaxis1,2
Acute medical illness
Average hospital LOS5 days
Usual duration of
administration with LOVENOX
6-11 days





See more dosing information for each indication with LOVENOX.

Get the information

Learn about the authorized generic
of LOVENOX that meets all quality
control standards.

Find out more
+
Important Safety Information
for LOVENOX®

Warning: spinal/epidural hematoma Epidural or spinal hematomas may occur in
patients who are anticoagulated with low